Diving deeper into to the evidence chains, Sulindac, an inhibitor of PTGS1 and PTGS2, has been predicted as a potential therapy for FXS by linking these two proteins to their involvement in Alzheimer’s disease and amyloid precursor protein (APP) processing (Fig. 3b). Here, PTGS2 is linked to early-onset autosomal dominant Alzheimer disease.